The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCarclo Regulatory News (CAR)

Share Price Information for Carclo (CAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 15.00
Bid: 13.00
Ask: 16.00
Change: 1.50 (11.54%)
Spread: 3.00 (23.077%)
Open: 13.10
High: 15.00
Low: 13.10
Prev. Close: 13.00
CAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Management Statement

4 Feb 2009 07:00

RNS Number : 7412M
Carclo plc
04 February 2009
 



For immediate release:  4 February 2009

Carclo plc

("Carclo" or "The Group")

Interim Management Statement

The Board is pleased to report that the group continues to trade in line with our expectations at the time of our Interim Statement in November 2008. The resilience of our specialist medical and optical businesses, together with strong design and development revenues in our specialist lighting business, have helped to offset the impact of weaker demand in the group's more difficult electronics and automotive markets.

In Technical Plastics, the medical businesses continue to trade well and win new contracts and LED optics volumes are growing. We have seen a reduction in volumes in this division's smaller markets, electronics and automotive components which together account for approximately 20% of group turnover. However, we are continuing to manage costs in order to maintain margins. The board has taken the decision to bring forward the planned closure of the Slough manufacturing facility and reduce future costs by redeploying the remaining production capacity to lower cost facilities within the UK. The division will retain a small technical support facility in the Slough area.

The Precision Products division delivered an excellent performance in the first half of the financial year. Our specialist lighting programmes for the supercar market have so far been largely unaffected by the turbulence in the automotive industry and design and development revenues from recent contract wins should help to underpin a very satisfactory performance for the full year. Whilst demand for antennas and cables has decreased, this has been mitigated by a good performance from our aerospace business which benefited from the acquisition of Jacottet Industrie in July 2008.

The group continues to invest in new technologies. Conductive Inkjet Technology ("CIT") is now producing volume samples of Radio-frequency identification ("RFID") components for a number of major companies in the industry and the feedback on both technical performance and achievement of cost targets is excellent. CIT's technology, which enables the design of innovative devices using printed electronics, is now being validated with customers across a range of applications in addition to RFID. These developments are very encouraging and we look forward to a significant step up in the pace of commercialisation at CIT.

Progress has also been good at Platform Diagnostics ("Platform"). This business has developed an innovative blood testing device using its patented Capillary Agglutination Technology alongside unique display and sensor systems developed by CIT. Since the half year, Carclo has increased its investment in Platform from 17.5% to 27.1% alongside our investment partner, BBI Holdings.

Since the interim results were announced, sterling has weakened against all major currencies. As the group generates a significant proportion of its profits in US dollars and Euros this has enhanced earnings. Net debt at the half year was £15.9 million. Translated at today's exchange rates this debt would be £19.5 million. To mitigate against further weakening of sterling we also converted approximately half of our US dollar debt to sterling at the end of November. We are generating cash from operations and debt remains controlled well within our total facilities of £31.9 million.

Overall, the group continues to show resilience in a challenging and volatile environment and remains well positioned in some exciting growth areas such as medical diagnostics and devices, LED optics and lighting, and printed electronics.

- ENDS -

Enquiries:

Carclo plc

01924 268040

Ian Williamson, Chief Executive

Robert Brooksbank, Finance Director

Weber Shandwick Financial

020 7067 0700

Terry Garrett or James White

Notes to editors

Carclo plc is a global supplier of technical plastic components. It is a public company whose shares are quoted on the London Stock Exchange.

70% of sales are derived from the supply of fine tolerance, injection moulded plastic components, which are used in medical, optical and electronics products. This business, Carclo Technical Plastics, operates internationally in a fast growing and dynamic market underpinned by rapid technological development.

30% of sales are derived from the supply of specialised precision products to the premium automotive and aerospace industries.

Carclo's strategy is to develop new technologies and products to drive future growth.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSUUUUAPUPBGQW
Date   Source Headline
30th Apr 20247:00 amRNSHolding(s) in Company
30th Apr 20247:00 amRNSHolding(s) in Company
26th Apr 20247:00 amRNSTrading Statement
17th Apr 20247:55 amRNSDirectorate Change
15th Apr 20243:55 pmRNSHolding(s) in Company
28th Feb 20247:00 amRNSDirectorate Change
14th Feb 20247:00 amRNSStrategic Consolidation & Tucson Facility Closure
9th Feb 20241:15 pmRNSHolding(s) in Company
29th Jan 202411:09 amRNSDirectorate Change
23rd Jan 20244:48 pmRNSHolding(s) in Company
6th Dec 202310:53 amRNSHolding(s) in Company
30th Nov 20237:00 amRNSHalf-year Report
16th Nov 20237:00 amRNSNotice of Interim Results & Investor Presentation
25th Oct 20233:16 pmRNSCarclo Strategic Decision to Close Derry Facility
22nd Sep 20237:00 amRNSDirector/PDMR Shareholding
31st Aug 20234:01 pmRNSResult of AGM
31st Aug 20237:00 amRNSTrading Update
21st Aug 20231:09 pmRNSDirectorate Change
31st Jul 202311:42 amRNSAnnual Financial Report
18th Jul 20237:00 amRNSBanking covenant update
12th Jul 20237:00 amRNSFinal Results
7th Jul 20237:00 amRNSNotice of Investor Meet Presentation
23rd Jun 20237:00 amRNSBanking covenant adjustment
21st Jun 20231:08 pmRNSNotice of Results
30th May 202310:07 amRNSUpdate on contract cancellation
17th May 20238:46 amRNSHolding(s) in Company
12th May 20239:38 amRNSHolding(s) in Company
14th Apr 20237:00 amRNSTrading Statement
31st Mar 202312:50 pmRNSBanking Covenant update
9th Mar 20239:56 amRNSHolding(s) in Company
24th Feb 20237:00 amRNSDirectorate Change
6th Jan 20234:17 pmRNSHolding(s) in Company
19th Dec 20224:40 pmRNSSecond Price Monitoring Extn
19th Dec 20224:35 pmRNSPrice Monitoring Extension
16th Dec 20221:15 pmRNSDirector/PDMR Shareholding
16th Dec 20221:11 pmRNSDirector/PDMR Shareholding
16th Dec 20221:10 pmRNSDirector/PDMR Shareholding
15th Dec 20227:00 amRNSTrading Update
14th Dec 20224:40 pmRNSSecond Price Monitoring Extn
14th Dec 20224:35 pmRNSPrice Monitoring Extension
9th Dec 20227:00 amRNSDirector/PDMR Shareholding
9th Dec 20227:00 amRNSDirector/PDMR Shareholding
7th Dec 20229:44 amRNSContract Cancellation
6th Dec 20226:29 pmRNSHolding(s) in Company - Replacement
5th Dec 20224:40 pmRNSSecond Price Monitoring Extn
5th Dec 20224:35 pmRNSPrice Monitoring Extension
30th Nov 20227:00 amRNSHalf-year Report
15th Nov 20227:05 amRNSNotice of Interim Results & Investor Presentation
15th Nov 20227:00 amRNSDirectorate Change
7th Nov 20227:00 amRNSBoard Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.